The CSIC has signed an R&D contract with the biotechnology company Tetraneuron for the development of agents able to block neuronal tetraploidization as a therapeutic method for Alzheimer's disease. This project will be carried out by the “Neuronal Generation and Degeneration in Vertebrates” group from the Cajal Institute as a “proof of concept” of a patent from this group, which has been licensed by Tetraneuron.